Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Sotirios Zarogiannis (Larisa, Greece), Erasmia Rouka, Georgios Vavougios, Evgeniy Solenov, Konstantinos Gourgoulianis, Chrissi Hatzoglou, Sotirios Zarogiannis. Effect of asbestos on gene expression of tight junctions components in malignant pleural mesothelioma. Eur Respir J 2016; 48: Suppl. 60, 5073

Member's Comments

No comment yet.

Related content which might interest you: Comparison between mesothelin and fibulin-3 detection in pleural malignant mesothelioma (MPM) patients Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Role of fibulin-3 in the diagnosis of malignant mesothelioma Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma Year: 2014 A novel hypothesis in benign pleural thickening in asbestos exposed patients Source: Annual Congress 2013 –Occupational respiratory diseases: obstructive, interstitial lung diseases and methods of diagnosis Year: 2013 Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 Association of biochemical determinants and fibrinous formation in malignant pleural effusion Source: International Congress 2016 – Malignant pleural disease: diagnosis and management Year: 2016 Volume quantification of malignant pleural mesothelioma Source: International Congress 2015 – Malignant pleural effusions and mesothelioma Year: 2015 Differential gene expression of two-pore-domain potassium channels in malignant pleural mesothelioma Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013 Role of tumor derived versican in experimental malignant pleural mesothelioma Source: International Congress 2016 – Mesothelioma and pleural disease: from the bench to the bedside Year: 2016 Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: In-vitro study Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015 Expression of YKL-40 and MIP-1a proteins in exudates and transudates: Biomarkers for differential diagnosis of pleural effusions? Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 High fluorescence cells in pleural fluid. Association with pleural malignancy Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 Management of malignant pleural mesothelioma Source: Hands-on Course 2013 - Medical Thoracoscopy Year: 2013 Management of malignant pleural mesothelioma Source: School Course 2014 - Medical Thoracoscopy Year: 2014 Management of malignant pleural mesothelioma Source: ERS Skills Course 2015 Year: 2015 Management of malignant pleural mesothelioma Source: ERS Course 2016 - Skills course on medical thoracoscopy Year: 2016 Management of malignant pleural mesothelioma Source: Hands-on Course 2012 - Medical Thoracoscopy Year: 2012 Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Prognostic factors in diffuse malignant pleural mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 755s Year: 2007